Intelligence Hub
Market analytics and operational performance indicators
Insider Trading - December 18, 2025
Director Saintil sold 5,000 shares ($272K) via 10b5-1 plan.
Brief
Merline Saintil, Director at Rocket Lab USA, sold 5,000 common shares on 12/17/2025 in multiple transactions at weighted-average prices from $53.82 to $56.48. Post-transaction direct holdings: 393,529 shares. Neutral signal due to pre-scheduled Rule 10b5-1 trading plan.
Detailed Brief
Merline Saintil, a Director, executed automatic sales of 5,000 common shares on December 17, 2025, pursuant to a Rule 10b5-1 trading plan adopted on September 17, 2025. The sales comprised: 2,533 shares at $53.8164 (range $53.36-$54.29), 1,767 at $54.824 ($54.37-$55.35), 500 at $55.668 ($55.37-$55.86), and 200 at $56.48 ($56.37-$56.59), totaling approximately $272,000. Following these, she holds 393,529 shares directly. No derivative activity reported. This appears to be a routine scheduled disposition with no indication of discretionary selling or unusual patterns.
Key Telemetry
- • Sold 5,000 shares (~1.3% of post-sale direct holdings of 393,529)
- • Executed under 10b5-1 plan adopted 9/17/2025 (standard scheduled sale)
- • Prices $53.36-$56.59; no specific price context like 52-week extremes provided
- • Small sale size; neutral timing, no earnings or announcement tie-in noted
Impact Vector
This pre-planned 10b5-1 sale signals neutral insider confidence, as it reflects automatic execution rather than discretionary action amid high prices.